Edward Lifesciences pays Boston Scientific $180m to end patent row
The settlement is seen as positive for the industry as a whole
Bengaluru — Edwards Lifesciences has paid rival Boston Scientific Corporation $180m as part of a settlement to end long-standing patent disputes between the two medical device makers. Boston Scientific and Edwards Lifesciences have been embroiled in a number of legal cases for several years involving heart valve replacement systems, including transcatheter aortic valves, in the US and Europe. All pending cases or appeals in courts and patent offices will be dismissed, the companies said in a joint statement on Tuesday. The valves are used in a relatively new procedure called transcatheter aortic valve replacement, or TAVR, in which the original heart valve is not surgically removed. The market for the devices is expected to reach $6.5bn by 2022, according to Jefferies. The settlement was a win-win for all, analysts said, with one noting that it could also be a positive for the industry as a whole. “This is the single largest end market in medical devices ... if growth were to decele...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.